8-K ·Filed Feb 26, 2026

INDV

Indivior Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001193125-26-073363
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of strong revenue growth, significant EBITDA expansion, and a substantial share repurchase program suggests the company is executing well on its strategy. Traders should monitor the success of the DTC campaign and the acceleration of SUBLOCADE dispense unit growth to the mid-teens in 2026, as this will be key to achieving the raised guidance.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INDV ▲ +11.12% at T+60d
LONG call ✓ call won +11.12% · α vs SPY +3.37% · entry $33.71 → $37.46
Entry anchored
Feb 25, 03:59 PM ET
via exchange tick
T+1d
-2.94%
call -2.94% · α -2.48%
$32.72
settled 7mo ago
T+5d
-4.92%
call -4.92% · α -3.80%
$32.05
settled 7mo ago
T+20d
-11.15%
call -11.15% · α -4.75%
$29.95
settled 6mo ago
T+60d
+11.12%
call +11.12% · α +3.37%
$37.46
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Indivior reported strong 2025 financial results with record SUBLOCADE net revenue of $856 million (up 13% YoY) and full-year GAAP net income of $210 million, a significant improvement from $7 million in 2024. The company entered Phase II of its 'Accelerate' agenda, reaffirmed 2026 guidance for 8% SUBLOCADE revenue growth and 30% adjusted EBITDA growth, and authorized a new $400 million share repurchase program.

Key Financial Metrics

Revenue
$1.2B
+4.0% YoY
Adj. EPS
$2.50
GAAP: $1.64
Guidance
$1,125 million to $1,195 million
maintained
Gross Margin
80%

Key Facts

  • Full-year 2025 total net revenue was $1.239 billion, up 4% YoY; SUBLOCADE net revenue was $856 million, up 13% YoY
  • Full-year 2025 GAAP net income was $210 million vs. $7 million in 2024; non-GAAP net income was $320 million vs. $240 million
  • Full-year 2025 adjusted EBITDA was $428 million, up 20% YoY
  • Company reaffirmed 2026 guidance: SUBLOCADE net revenue of $905-$945 million (+8% YoY) and adjusted EBITDA of $535-$575 million (+30% YoY)
  • Authorized a new $400 million share repurchase program with an 18-month term

Financial Impact

The company generated $428 million in adjusted EBITDA in 2025 and expects to grow this to $535-$575 million in 2026, representing a 30% increase. The $400 million share repurchase program represents approximately 18% of the company's current market capitalization.

revenueepsebitdacashFlowdilution

Segment Breakdown

SegmentRevenueGrowth
SUBLOCADE$856.0M+13.0%

Risk Factors

  • The company paid $295 million to conclude the legacy DOJ matter, which reduced cash and investments to $222 million
  • 2026 total net revenue guidance is down 6% YoY, which could concern investors despite the focus on higher-margin SUBLOCADE growth
  • The company's leverage ratio of 0.7x could limit financial flexibility for business development opportunities

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073363
Document: d713689dex993.htm0001193125-26-073363
Document: d713689dex992.htm0001193125-26-073363
Document: d713689d8k.htm0001193125-26-073363
Document: 0001193125-26-073363-index-headers.html0001193125-26-073363
Document: 0001193125-26-073363-index.html0001193125-26-073363
Document: 0001193125-26-073363.txt0001193125-26-073363
18 reports for INDV
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+60▲ +21.73%Apr 24, 2026
Filters
Rows
Reports for INDV — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
EFFECT
NEUTRAL ★ 4/10
$34.47 $35.53▲ +3.08%▲ +2.97%$35.71 (+3.60%)
Aug 28, 2026
4w ago
S-4
NEUTRAL ★ 6/10
$34.93 $34.32▼ −1.75%▼ −1.60%$35.71 (+2.23%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 7/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$40.51 $40.22▼ −0.72%▼ −1.19%$35.71 (−11.85%)
Jun 12, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$38.40 $38.32▼ −0.21%▲ +1.17%$35.71 (−7.01%)
May 15, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$36.54 $37.81▲ +3.48%▲ +1.86%$35.71 (−2.27%)
May 4, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$38.98 $38.84▼ −0.36%▼ −3.30%$35.71 (−8.39%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (64h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access